research Scalp Hypothermia for the Prevention of Chemotherapy-Induced Alopecia in Breast Cancer
The study evaluated the efficacy of scalp hypothermia (SHT) in preventing chemotherapy-induced alopecia in 75 breast cancer patients. Conducted from 2016 to 2023, the study found that SHT, using the Orbis II device, resulted in complete hair preservation in 57.3% of patients. Grade 1 and 2 alopecia were observed in 25.4% and 12% of patients, respectively. Side effects were minimal, with 16% experiencing cold sensations or headaches, and 3 patients discontinuing due to intolerance. No scalp metastases were reported. Overall, SHT was deemed effective in reducing alopecia, aiding in patients' psychological and social well-being.